• Asian Pacific Journal of Cancer Prevention
• /
• 제16권11호
• /
• pp.4515-4520
• /
• 2015

GELOX (gemcitabine, oxaliplatin and L-asparaginase) regimen showed an impressive result in our previous study, but the effect of this new regimen is still dissatisfying for some patients, so it is necessary to identify which patients will benefit from this regimen. A total of fifty-one cases with nasal natural killer/T-cell lymphoma receiving initial GELOX chemotherapy were enrolled in this study. The ki-67 expression detected by immunohistochemistry (IHC) in the specimens ranged from 10% to 90%, with a median value of 70%, so cases higher than the median value (${\geq}70%$) were defined as high ki-67 expression, and the others were designated as low ki-67 expression. The response rate had no statistical difference between low ki-67 expression group and high ki-67 expression group (P=0.291) though the value in the former group was relatively high. After a median follow-up of 18.03 months, the 3-year progression-free survival (PFS) for patients with low ki-67 expression was significantly higher than those with high ki-67 expression (83.8% vs. 47.9%, P=0.038). In the stage I/II subgroup, 3-year PFS and overall survival (OS) were statistically higher in the patients with low ki-67 expression than those with high ki-67 expression. Multivariate analysis revealed high ki-67 expression was an independent prognostic factor for PFS. These results suggest that low ki-67 expression can predict a good response of GELOX in these patients, and the combination of ki-67 expression and early stage is helpful to identify an excellent prognosis subgroup from patients receiving GELOX in this disease.

• 대한두경부종양학회지
• /
• 제40권1호
• /
• pp.49-53
• /
• 2024

Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma, with an incidence of about 0.8% to 5% per million people per year, accounting for 1% of soft tissue sarcomas. In its early stage, DFSP is typically found as a violet or pinkish macule or patch, and it can develop into a palpable mass with ulceration or bleeding. The standard treatment for DFSP is wide local excision of the tumor with a 2- to 3-cm negative margin, and radiation therapy or chemotherapy can be conducted with surgical treatment. A 35-year-old man had a palpable mass on the left side of his occipital scalp without color change, ulceration, or bleeding, which typically are present in malignancy. A magnetic resonance imaging (MRI) scan showed a 3-cm homogenous enhanced mass without adhesion between the scalp and the mass. Unexpectedly, a biopsy revealed the round mass to be DFSP. A wide excision and rotation of the scalp flap were performed. The patient recovered without any complications and received adjuvant radiotherapy at a dose of 60 Gray (Gy) for six weeks. There was no recurrence through six months of follow-up. Here we report this unique case of DFSP with atypical presentation.

• 한국정보통신학회:학술대회논문집
• /
• 한국정보통신학회 2015년도 춘계학술대회
• /
• pp.622-624
• /
• 2015

암 세포 주변의 저산소증은 방사선, 항암치료제, 절제술 등을 이용한 항암치료법에 중요한 역할을 하는데, 특히 암세포 주변의 모세혈관 내에서의 산소의 이동 분석은 암의 발달 및 전이, 주변 혈관의 생성과 변이에 직간접적 영향을 미친다. 따라서 현재 암 병변 주변의 모세혈관 내 헤모글로빈 산소포화도를 측정하고 혈관의 생성 및 변이상태를 측정하는 연구가 활발하게 진행되고 있지만, 대부분의 계측장비는 침습적인 방법으로 진행되며, 해상도 또한 기대이하의 공간 및 시간영역을 제공하는 한계가 있다. 따라서 본 연구에서는 비침습적 헤모글로빈 산소포화도 이미지와 다양한 이미지프로세싱 기법을 이용하여 실시간 혈관변화의 분석을 통해 암 혈관 생성 및 변이의 특성을 제공할 수 있는 초분광 이미징 시스템 활용 방법을 제시하고자 한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권7호
• /
• pp.3261-3265
• /
• 2014

Background: To evaluate serum VEGF-A levels in squamous cell carcinoma of head and neck (SCCHN) patients and relationships with response to therapy. Materials and Methods: Serum VEGF-A levels in patients (n=72) treated with radiotherapy (RT) or radio-chemotherapy (RCT) and controls (n=40) were measured by ELISA. Results: Serum VEGF-A levels of the SCCHN cases were significantly higher (p=0.001) than in healthy controls, and in patients with positive as compared to negative lymph node status (p=0.004). Similarly, patients with advanced stage (Stage III-IV) disease had more greatly elevated levels of serum VEGF-A level than their early stage (Stage I-II) counterparts (p=0.001). In contrast, there was no significant difference (p=0.57) in serum level of VEGF-A in patients with advanced T-stage (T3-4) as compared to early stage (T1-2). Similarly, patients with distant metastasis had no significant (p=0.067) elevation in serum VEGF-A level as compared to non-metastatic disease. However, the non-responder patients had significantly higher serum VEGF-A level as compared to responders (p=0.001). Conclusions: Our results suggest that the serum VEGF-A level may be a useful biomarker for the prediction of response to therapy in SCCHN.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권8호
• /
• pp.3533-3536
• /
• 2014

Background: Breast cancer is one of the most common cancers in women in the world. Health-related quality of life (HRQL) at treatment endpoint in cancer clinical trials is widely considered to be increasingly important. The aim of this review was to provide a literature-based assessment of the validity, reliability and responsiveness of breast cancer-specific HRQL instruments in women breast cancer patients. Materials and Methods: The databases consulted were Medline, PubMed, and Embase. The inclusion criteria required studies to: (1) involve use of HRQL measures; (2) cover women with breast cancer under standard treatment (surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy); (3) involve the validity, reliability, or responsiveness of HRQL; (4) deal with validation of breast cancer-specific HRQL instruments. Results: A total of 16 studies were identified through the literature search that met the 4 inclusion criteria. Some seven instruments were assessed among these 16 studies: EORTC QLQ-BR23, FACT-B, FACT-ES, HFRDIS, LSQ-32, QLICP-BR, and SLDS-BC. EORTC QLQ-BR23, FACT-B, LSQ-32, QLICP-BR, and SLDS-BC are more general breast cancer-specific HRQL instruments. FACT-EB is the endocrine subscale combined with FACT-B in order to measure the side effects and putative benefits of hormonal treatment administered in breast cancer patients. HFRDIS is the HRQL measure focusing on hot flash concerns. Conclusions: This paper provides an overall understanding on the currently available breast cancer-specific HRQL instruments in women breast cancer patients.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제14권1_2호
• /
• pp.97-104
• /
• 1992

본 경북대학교 치과대학 구강외과학 교실 및 대구 가톨릭대학병원 구강악안면외과학 교실에서는 3명의 구강암 환자에서 각각의 상태에 따라 국소적 경부곽청술, 양측성 보존적 경부곽청술, 고전적 경부곽청술 및 술후 방사선요법을 시행하여 다소의 지견을 얻었기에 보고하는 바이다. 1. 국소적 경부곽청술을 시행한 증례 1($T2_N0_M0$)의 경우에는 아주 만족한 결과를 나타내었다. 2. 양측성 보존적 경부곽청술을 시행한 증례 2($_T3_N1_M0$)에서는 거의 전이가 일어나지 않는다고 알려진 후경삼각부위에서 술후 약 8개월만에 전이가 관찰되어 화학적 항암요법을 시행하였으나 술후 13개월 만에 사망하였음. 3. 고전적 경부곽청술을 시행한 증례 3($_T2_N1_M0$)에서는 현재 아주 양호한 예후를 보이고 있다.

• Journal of Ginseng Research
• /
• 제36권1호
• /
• pp.86-92
• /
• 2012

The glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite combination treatments of radiation and chemotherapy, the survival periods are very short. Therefore, this study was conducted to assess the potential of ginsenoside $F_2$ (F2) to treat GBM. In in vitro experiments with glioblastoma cells U373MG, F2 showed the cytotoxic effect with $IC_{50}$ of 50 ${\mu}g/mL$ through apoptosis, confirmed by DNA condensation and fragmentation. The cell population of cell cycle sub-G1 as indicative of apoptosis was also increased. In xenograft model in SD rats, F2 at dosage of 35 mg/kg weight was intravenously injected every two days. This reduced the tumor growth in magnetic resonance imaging images. The immunohistochemistry revealed that the anticancer activity might be mediated through inhibition of proliferation judged by Ki67 and apoptosis induced by activation of caspase-3 and -8. And the lowered expression of CD31 showed the reduction in blood vessel densities. The expression of matrix metalloproteinase-9 for invasion of cancer was also inhibited. The cell populations with cancer stem cell markers of CD133 and nestin were reduced. The results of this study suggested that F2 could be a new potential chemotherapeutic drug for GBM treatment by inhibiting the growth and invasion of cancer.

• Radiation Oncology Journal
• /
• 제5권1호
• /
• pp.23-30
• /
• 1987

I, II기 원방성 위장관 임파종 환자 38명의 수술후 방사선 치료 결과를 분석하였다. 방사선 치료 중 6예의 원격전이가 관찰되었고, 방사선 치료 전 병소의 크기에 따른 치료실패율은 5cm 미만에서 $31\%$, 5cm 이상에서 $75\%$로 유의한 차이가 있었다(p<0.05). 방사선 치료를 계획대로 받은 28예서 5년 생존율은 $69.2\%$였고, 그중 병소의 크기가 5cm 미만인 경우는 $72\%$였다. 병소의 크기에 따른 5년 무병생존율에도 차이가 있어 5cm 미만인 경우엔 $71\%$, 5cm 이상인 경우엔 $25\%$였다(p<0.05). 반면에 병기, 병리학적 유형 및 원발장기 등에 따른 생존율의 차이는 유의하지 않았다. 따라서 방사선 치료 전 병소 크기가 5cm 미만일 경우는 완치가 가능하나, 5cm 이상으로 클 경우에는 항암화학요법의 병용이 시도될 수 있겠다.

• 대한두경부종양학회지
• /
• 제16권2호
• /
• pp.216-219
• /
• 2000

Small cell carcinoma usually occurs in lung, but extrapulmonary small cell carcinomas can occur in any sites of body. Most sites of extrapulmonary small cell carcinoma reported were esophagus. And small cell carcinomas occurred in head and neck area were reported rarely. Extrapulmonary small cell carcinoma could be diagnosed when there is no evidence of primary lung lesion on chest X-ray, CT scan of chest and bronchoscopy. The authors experienced a case of small cell carcinoma of left submandibular lymph node in 64-year-old male patient. Biopsy specimen showed poorly differentiated carcinoma but immunohistochemical study showed small cell carcinoma. The chest X-ray and CT scan of chest showed no evidence of primary lung lesion. The patient received chemotherapy(etoposide plus cisplatin) and concurrent chemoradiotherapy using weekly taxol which resulted in good clinical remission. He is still alive 8 months after diagnosis without evidence of lung disease. We report our case with a brief review of literatures.

• 대한두경부종양학회지
• /
• 제28권1호
• /
• pp.42-45
• /
• 2012

Small cell carcinoma mainly occurs in the lung. Approximately 2.5-5% of small cell carcinomas are primary extrapulmonary which are commonly found in the esophagus, GI tract, skin, uterus, and urinary tract. Small cell carcinoma of the head and neck is extremely rare and its prognosis is poor. We report a case of supraglottic small cell carcinoma with cervical lymph node and rib metastasis in a 75-year-old man. The patient was treated with sequential combination of chemotherapy and radiotherapy, but the cancer has progressed. We concluded that we have to find an effective therapy for laryngeal small cell carcinoma.